Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

IVIG therapy is given as an IV infusion. This means a healthcare professional will start an IV line, typically in your arm, ...

The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for ...

This latter effect is important both because therapy in CIDP is usually episodic and because IVIg is typically a more expensive treatment and indefinite monthly infusions would be quite resource ...

The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for ...